Open AccessThe effectiveness of Wilms tumor screening in Beckwith–Wiedemann spectrum
Author(s) -
Alessandro Mussa,
Kelly A. Duffy,
Diana Carli,
Jessica R Griff,
Riccardo Fagiano,
Jonida Kupa,
Garrett M. Brodeur,
Giovanni Battista Ferrero,
Jennifer M. Kalish
Publication year - 2019
Publication title -
journal of cancer research and clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.338
H-Index - 94
eISSN - 1432-1335
pISSN - 0171-5216
DOI - 10.1007/s00432-019-03038-3
Subject(s) - beckwith–wiedemann syndrome , medicine , incidence (geometry) , epidemiology , wilms tumour , wilms' tumor , population , pediatrics , hematology , biochemistry , gene expression , chemistry , physics , environmental health , optics , dna methylation , gene
It is well documented that patients with Beckwith-Wiedemann spectrum (BWS) have a significantly higher risk of developing Wilms tumor (WT) than the general population. There has been little research on the timing of WT diagnosis in BWS in regard to optimizing suggested screening protocols.